Ecopia, Kosan Pen Microbial Sequencing Deal | GenomeWeb

NEW YORK, Oct 20 – Just two days after its birth as a spin off from Theratechnologies, microbial genomics company Ecopia BioSciences said Friday it had signed a microbial sequencing deal with Kosan BioSciences.

Under the agreement, Ecopia will apply its genomics platform in order to discover the genes of a particular microorganism that direct the synthesis of an undisclosed small molecule, which is of interest to Kosan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.